Abstract
Huntington’s disease (HD) is a chronic progressive neurodegenerative condition where new markers of disease progression are needed. So far no disease-modifying interventions have been found, and few interventions have been proven to alleviate symptoms. This may be partially explained by the lack of reliable indicators of disease severity, progression, and phenotype.
Biofluid biomarkers may bring advantages in addition to clinical measures, such as reliability, reproducibility, price, accuracy, and direct quantification of pathobiological processes at the molecular level; and in addition to empowering clinical trials, they have the potential to generate useful hypotheses for new drug development.
In this chapter we review biofluid biomarker reports in HD, emphasizing those we feel are likely to be closest to clinical applicability.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Travessa AM, Rodrigues FB, Mestre TA et al (2016) Fifteen years of clinical trials in Huntington’s disease: too many clinical trial failures. Mov Disord 31:S365–S366
Mestre T, Ferreira J, Coelho MM et al (2009) Therapeutic interventions for symptomatic treatment in Huntington’s disease. Cochrane Database Syst Rev (3):Cd006456
Rodrigues FB, Mestre T, Duarte SD et al (2017) [122] Therapeutic interventions for symptomatic treatment in Huntington’s disease – a Cochrane review. In: CHDI (ed) CHDI 12th annual HD therapeutics conference, St Julien, Malta, 2017
Mestre T, Ferreira J, Coelho MM et al (2009) Therapeutic interventions for disease progression in Huntington’s disease. Cochrane Database Syst Rev (3):Cd006455
Rodrigues FB, Mestre T, Duarte SD et al (2017) [121] Therapeutic interventions for disease progression in Huntington’s disease – a Cochrane review. In: CHDI 12th annual HD therapeutics conference, St Julien, Malta, 2017
Wild EJ (2016) Huntington’s disease: the most curable incurable brain disorder? EBioMedicine 8:3–4
Rodrigues FB, Wild EJ (2017) Clinical trials corner: September 2017. J Huntingtons Dis 6(3):255–263. https://doi.org/10.3233/JHD-170262
Rodrigues FB, Wild EJ (2018) Huntignton's disease clinical trials corner: February 2018. J Huntingtons Dis 7(1):89–98. https://doi.org/10.3233/JHD-189001
Ross CA, Aylward EH, Wild EJ et al (2014) Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol 10:204–216
Tabrizi SJ, Scahill RI, Owen G et al (2013) Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: analysis of 36-month observational data. Lancet Neurol 12:637–649
Biglan KM, Zhang Y, Long JD et al (2013) Refining the diagnosis of Huntington disease: the PREDICT-HD study. Front Aging Neurosci 5:12. https://doi.org/10.3389/fnagi.2013.00012
Byrne LM, Wild EJ (2016) Cerebrospinal fluid biomarkers for Huntington’s disease. J Huntingtons Dis 5:1–13
The Huntington’s Disease Collaborative Research Group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. Cell 72:971–983
Gusella JF, Wexler NS, Conneally PM et al (1983) A polymorphic DNA marker genetically linked to Huntington’s disease. Nature 306:234–238
Cattaneo E, Zuccato C, Tartari M (2005) Normal huntingtin function: an alternative approach to Huntington’s disease. Nat Rev Neurosci 6:919–930
Wetzel R (2012) Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence. J Mol Biol 421:466–449
Weiss A, Träger U, Wild EJ et al (2012) Mutant huntingtin fragmentation in immune cells tracks Huntington’s disease progression. J Clin Investig 122:3731–3736
Moscovitch-Lopatin M, Weiss A, Rosas HD et al (2010) Optimization of an HTRF assay for the detection of soluble mutant huntingtin in human buffy coats: a potential biomarker in blood for Huntington disease. PLoS Curr 2:Rrn1205
Moscovitch-Lopatin M, Goodman RE, Eberly S et al (2013) HTRF analysis of soluble huntingtin in PHAROS PBMCs. Neurology 81:1134–1140
Massai L, Petricca L, Magnoni L et al (2013) Development of an ELISA assay for the quantification of soluble huntingtin in human blood cells. BMC Biochem 14:34
Southwell AL, Smith SEP, Davis TR et al (2015) Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Sci Rep 5:12166
Wild EJ, Boggio R, Langbehn D et al (2015) Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington’s disease patients. J Clin Investig 125:1979–1986
Weiss A, Abramowski D, Bibel M et al (2009) Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington’s disease. Anal Biochem 395:8–15
Paganetti P, Weiss A, Trapp M et al (2009) Development of a method for the high-throughput quantification of cellular proteins. Chembiochem 10:1678–1688
Fodale V, Boggio R, Daldin M et al (2017) Validation of ultrasensitive mutant huntingtin detection in human cerebrospinal fluid by single molecule counting immunoassay. J Huntingtons Dis 6:349–361. https://doi.org/10.3233/JHD-170269
Dunlap CB (1927) Pathologic changes in Huntington’s chorea: with special reference to the corpus striatum. Arch Neurol Psychiatr 18:867–943
Terrence CF, Delaney JF, Alberts MC (1977) Computed tomography for Huntington’s disease. Neuroradiology 13:173–175
Tabrizi SJ, Langbehn DR, Leavitt BR et al (2009) Biological and clinical manifestations of Huntington’s disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet Neurol 8:791–801
Tabrizi SJ, Scahill RI, Durr A et al (2011) Biological and clinical changes in premanifest and early stage Huntington’s disease in the TRACK-HD study: the 12-month longitudinal analysis. Lancet Neurol 10:31–42
Tabrizi SJ, Reilmann R, Roos RAC et al (2012) Potential endpoints for clinical trials in premanifest and early Huntington’s disease in the TRACK-HD study: analysis of 24 month observational data. Lancet Neurol 11:42–53
Paulsen JS, Langbehn DR, Stout JC et al (2008) Detection of Huntington’s disease decades before diagnosis: the Predict-HD study. J Neurol Neurosurg Psychiatry 79:874–880
Constantinescu R, Romer M, Oakes D et al (2009) Levels of the light subunit of neurofilament triplet protein in cerebrospinal fluid in Huntington’s disease. Parkinsonism Relat Disord 15:245–248
Rodrigues FB, Byrne LM, Tabrizi SJ et al (2016) CSF inflammatory and cell death biomarkers in Huntington’s disease – an exploratory cross-sectional study. Mov Disord 31:S353
Niemela V, Landtblom AM, Blennow K, Sundblom J (2017) Tau or neurofilament light—which is the more suitable biomarker for Huntington’s disease? PLoS One 12:e0172762
Byrne LM, Rodrigues FB, Blennow K et al (2017) Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington’s disease: a retrospective cohort analysis. Lancet Neurol 16:601–609
Vinther-Jensen T, Börnsen L, Budtz-Jørgensen E, Ammitzbøll C, Larsen IU, Hjermind LE, Sellebjerg F, Nielsen JE (2016) Selected CSF biomarkers indicate no evidence of early neuroinflammation in Huntington disease. Neurol Neuroimmunol Neuroinflamm 3:e287. https://doi.org/10.1212/NXI.0000000000000287
Niemelä V, Burman J, Blennow K, Zetterberg H, Larsson A, Sundblom J (2018) Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington’s disease. PLoS One 13:e0193492. https://doi.org/10.1371/journal.pone.0193492
Johnson EB, Byrne LM, Gregory S et al (2018) Neurofilament light protein in blood predictsregional atrophy in Huntington disease. Neurology 90:e717–e723. https://doi.org/10.1212/WNL.0000000000005005
Wild EJ, Petzold A, Keir G, Tabrizi SJ (2007) Plasma neurofilament heavy chain levels in Huntington’s disease. Neurosci Lett 417:231–233
Constantinescu R, Romer M, Zetterberg H et al (2011) Increased levels of total tau protein in the cerebrospinal fluid in Huntington’s disease. Parkinsonism Relat Disord 17:714–715
Rodrigues FB, Byrne L, McColgan P et al (2016) Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington’s disease. J Neurochem 139:22–25
Stoy N, Mackay GM, Forrest CM et al (2005) Tryptophan metabolism and oxidative stress in patients with Huntington's disease. J Neurochem 93:611–623
Silajdzic E, Rezeli M, Vegvari A et al (2013) A critical evaluation of inflammatory markers in Huntington’s disease plasma. J Huntingtons Dis 2:125–134
Vinther-Jensen T, Budtz-Jørgensen E, Simonsen AH, Nielsen JE, Hjermind LE (2014) YKL-40 in cerebrospinal fluid in Huntington’s disease--a role in pathology or a nonspecific response to inflammation? Parkinsonism Relat Disord 20:1301–1303
Griffin WS, Stanley LC, Ling C et al (1989) Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A 86:7611–7615
Petzold A (2005) Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J Neurol Sci 233:183–198
Cairns NJ, Lee VM, Trojanowski JQ (2004) The cytoskeleton in neurodegenerative diseases. J Pathol 204:438–449
Zetterberg H, Smith DH, Blennow K (2013) Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood. Nat Rev Neurol 9:201–210
Fernandez-Nogales M, Cabrera JR, Santos-Galindo M et al (2014) Huntington’s disease is a four-repeat tauopathy with tau nuclear rods. Nat Med 20:881–885
Vuono R, Winder-Rhodes S, de Silva R et al (2015) The role of tau in the pathological process and clinical expression of Huntington’s disease. Brain 138:1907–1918
Gisslen M, Price RW, Andreasson U et al (2016) Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine 3:135–140
Steinacker P, Semler E, Anderl-Straub S et al (2017) Neurofilament as a blood marker for diagnosis and monitoring of primary progressive aphasias. Neurology 88:961–969
Rojas JC, Karydas A, Bang J et al (2016) Plasma neurofilament light chain predicts progression in progressive supranuclear palsy. Ann Clin Transl Neurol 3:216–225
Rohrer JD, Woollacott IO, Dick KM et al (2016) Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 87:1329–1336
Meeter LH, Dopper EG, Jiskoot LC et al (2016) Neurofilament light chain: a biomarker for genetic frontotemporal dementia. Ann Clin Transl Neurol 3:623–636
Lu CH, Macdonald-Wallis C, Gray E et al (2015) Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84:2247–2257
Gaiottino J, Norgren N, Dobson R et al (2013) Increased neurofilament light chain blood levels in neurodegenerative neurological diseases. PLoS One 8:e75091
Björkqvist M, Wild EJ, Tabrizi SJ (2009) Harnessing immune alterations in neurodegenerative diseases. Neuron 64:21–24
Dalrymple A, Wild EJ, Joubert R et al (2007) Proteomic profiling of plasma in Huntington’s disease reveals neuroinflammatory activation and biomarker candidates. J Proteome Res 6:2833–2840
Miller JR, Lo KK, Andre R et al (2016) RNA-Seq of Huntington’s disease patient myeloid cells reveals innate transcriptional dysregulation associated with proinflammatory pathway activation. Hum Mol Genet 25:2893–2904
Wild EJ, Tabrizi SJ (2014) Targets for future clinical trials in Huntington’s disease: What's in the pipeline? Mov Disord 29:1434–1445
A Clinical Study in Subjects With Huntington’s Disease to Assess the Efficacy and Safety of Three Oral Doses of Laquinimod (2014) Bethesda (MD): National Library of Medicine (US). https://ClinicalTrials.gov/show/NCT02215616. Accessed 02 Mar 2016
Rodrigues FB, Byrne LM, McColgan P et al (2016) Cerebrospinal fluid inflammatory biomarkers reflect clinical severity in Huntington’s disease. PLoS One 11:e0163479
Mochel F, Charles P, Seguin F et al (2007) Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One 2:e647
Björkqvist M, Wild EJ, Thiele J et al (2008) A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington’s disease. J Exp Med 205:1869–1877
Wang R, Ross CA, Cai H et al (2014) Metabolic and hormonal signatures in pre-manifest and manifest Huntington’s disease patients. Front Physiol 5:231
Leblhuber F, Walli J, Jellinger K et al (1998) Activated immune system in patients with Huntington’s disease. Clin Chem Lab Med 36:747–750
Sanchez-Lopez F, Tasset I, Aguera E et al (2012) Oxidative stress and inflammation biomarkers in the blood of patients with Huntington’s disease. Neurol Res 34:721–724
Trager U, Andre R, Lahiri N et al (2014) HTT-lowering reverses Huntington’s disease immune dysfunction caused by NF B pathway dysregulation. Brain 137:819–833
Chang K-H, Wu Y-R, Chen Y-C, Chen C-M (2015) Plasma inflammatory biomarkers for Huntington’s disease patients and mouse model. Brain Behav Immun 44:121–127
Forrest CM, Mackay GM, Stoy N et al (2010) Blood levels of kynurenines, interleukin-23 and soluble human leucocyte antigen-G at different stages of Huntington’s disease. J Neurochem 112:112–122
Squitieri F, Orobello S, Cannella M et al (2009) Riluzole protects Huntington disease patients from brain glucose hypometabolism and grey matter volume loss and increases production of neurotrophins. Eur J Nucl Med Mol Imaging 36:1113–1120
Battaglia G, Cannella M, Riozzi B et al (2011) Early defect of transforming growth factor beta1 formation in Huntington’s disease. J Cell Mol Med 15:555–571
Mattsson N, Tabatabaei S, Johansson P et al (2011) Cerebrospinal fluid microglial markers in Alzheimer’s disease: elevated chitotriosidase activity but lack of diagnostic utility. Neuromolecular Med 13:151–159
Byrne LM, Rodrigues FB, Johnson EB, De Vita E, Blennow K, Scahill R, Zetterberg H, Heslegrave A, Wild EJ (2018) Cerebrospinal fluid neurogranin and TREM2 in Huntington’s disease. Sci Rep. 8. https://doi.org/10.1038/s41598-018-21788-x
Huang Y-C, Wu Y-R, Tseng M-Y et al (2011) Increased prothrombin, apolipoprotein A-IV, and haptoglobin in the cerebrospinal fluid of patients with Huntington’s disease. PLoS One 6:e15809. https://doi.org/10.1371/journal.pone.0015809
Christofides J, Bridel M, Egerton M et al (2006) Blood 5-hydroxytryptamine, 5-hydroxyindoleacetic acid and melatonin levels in patients with either Huntington’s disease or chronic brain injury. J Neurochem 97:1078–1088
Wild E, Magnusson A, Lahiri N et al (2011) Abnormal peripheral chemokine profile in Huntington’s disease. PLoS Curr 3:RRN1231
Krzyszton-Russjan J, Zielonka D, Jackiewicz J et al (2013) A study of molecular changes relating to energy metabolism and cellular stress in people with Huntington’s disease: looking for biomarkers. J Bioenerg Biomembr 45:71–85
Bouwens JA, Hubers AA, van Duijn E et al (2014) Acute-phase proteins in relation to neuropsychiatric symptoms and use of psychotropic medication in Huntington’s disease. Eur Neuropsychopharmacol 24:1248–1256
Tasset I, Sanchez-Lopez F, Aguera E et al (2012) NGF and nitrosative stress in patients with Huntington’s disease. J Neurol Sci 315(1–2):133–136
Phillipson OT, Bird ED (1977) Plasma glucose, non-esterified fatty acids and amino acids in Huntington’s chorea. Clin Sci Mol Med 52:311–318
Duran R, Barrero FJ, Morales B et al (2010) Oxidative stress and plasma aminopeptidase activity in Huntington’s disease. J Neural Transm 117:325–332
Josefsen K, Nielsen SM, Campos A et al (2010) Reduced gluconeogenesis and lactate clearance in Huntington’s disease. Neurobiol Dis 40:656–662
Passonneau J, Lowry O (1993) Enzymatic analysis: a practical guide. Humana Press, NJ
Ciammola A, Sassone J, Sciacco M et al (2011) Low anaerobic threshold and increased skeletal muscle lactate production in subjects with Huntington’s disease. Mov Disord 26:130–137
Banks WA, Plotkin SR, Kastin AJ (1995) Permeability of the blood-brain barrier to soluble cytokine receptors. Neuroimmunomodulation 2:161–165
Aronson NN, Blanchard CJ, Madura JD (1997) Homology modeling of glycosyl hydrolase family 18 enzymes and proteins. J Chem Inf Comput Sci 37:999–1005
Bonneh-Barkay D, Bissel SJ, Kofler J et al (2012) Astrocyte and macrophage regulation of YKL-40 expression and cellular response in neuroinflammation. Brain Pathol 22:530–546
Cooper AJL, Jeitner TM, Gentile V, Blass JP (2002) Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG)n/Qn-expansion diseases? Neurochem Int 40:53–67
Jeitner TM, Bogdanov MB, Matson WR et al (2008) Nε-(γ-l-Glutamyl)-l-lysine (GGEL) is increased in cerebrospinal fluid of patients with Huntington’s disease. J Neurochem 79:1109–1112
Jeitner TM, Matson WR, Folk JEBlass JP, Cooper AJL (2008) Increased levels of γ-glutamylamines in Huntington disease CSF. J Neurochem 106:37–44
Raptor Plans to Advance RP103 in a Registration Study in Huntington’s Disease Based on Favorable Treatment Effects at 36 Months in CYST-HD Trial (2015). http://www.prnewswire.com/news-releases/raptor-plans-to-advance-rp103-in-a-registration-study-in-huntingtons-disease-based-on-favorable-treatment-effects-at-36-months-in-cyst-hd-trial-300191131.html
Enna SJ, Wood JH, Snyder SH (1977) γ-Aminobutyric acid (GABA) in human cerebrospinal fluid: radioreceptor assay. J Neurochem 28:1121–1124
Manyam NV, Hare TA, Katz L, Glaeser BS (1978) Huntington’s disease. Cerebrospinal fluid GABA levels in at-risk individuals. Arch Neurol 35:728–730
Böhlen P, Tell G, Schechter PJ et al (1980) Cerebrospinal fluid homocarnosine in Huntington’s disease. Life Sci 26:1009–1012
Uhlhaas S, Lange H, Wappenschmidt J, Olek K (1986) Free and conjugated CSF and plasma GABA in Huntington’s chorea. Acta Neurol Scand 74:261–265
Bonnet AM, Tell G, Schechter PJ et al (1987) Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich’s ataxia, Parkinson’s disease, and Huntington’s chorea. Mov Disord 2:117–123
Nicoli F, Vion-Dury J, Maloteaux JM et al (1993) CSF and serum metabolic profile of patients with Huntington’s chorea: a study by high resolution proton NMR spectroscopy and HPLC. Neurosci Lett 154(1–2):47–51
Wagner L, Bjorkqvist M, Lundh SH et al (2016) Neuropeptide Y (NPY) in cerebrospinal fluid from patients with Huntington’s disease: increased NPY levels and differential degradation of the NPY fragment. J Neurochem 137:820–837
Consolo S, Ladinsky H, Bianchi S, Caraceni T (1977) The cerebrospinal fluid choline levels in patients with Huntington’s chorea. Negative effect of haloperidol treatment. Arch Psychiatr Nervenkr 223:265–270
Saelens JK, Allen MP, Simke JP (1970) Determination of acetylcholine and choline by an enzymatic assay. Arch Int Pharmacodyn Ther 186:279–286
Manyam BV, Giacobini E, Colliver JA (1990) Cerebrospinal fluid acetylcholinesterase and choline measurements in Huntington’s disease. J Neurol 237:281–284
McCaman MW, Tomey LR, McCaman RE (1968) Radiomimetric assay of acetylcholinesterase activity in submicrogram amounts of tissue. Life Sci 7:233–244
Johnson CD, Russell RL (1975) A rapid, simple radiometric assay for cholinesterase, suitable for multiple determinations. Anal Biochem 64:229–238
St Clair DM, Brock DJ, Barron L (1986) A monoclonal antibody assay technique for plasma and red cell acetylcholinesterase activity in Alzheimer’s disease. J Neurol Sci 73:169–176
Garrett MC, Soares-da-Silva P (1992) Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in Huntington’s disease: evidence for an overactive dopaminergic brain transmission. J Neurochem 58:101–106
Belendiuk K, Belendiuk GW, Freedman DX (1980) Blood monoamine metabolism in Huntington’s disease. Arch Gen Psychiatry 37:325–332
Weise VK, Kopin IJ (1976) Assay of cathecholamines in human plasma: studies of a single isotope radioenzymatic procedure. Life Sci 19:1673–1685
Caraceni T, Panerai AE, Paratl EA et al (1977) Altered growth hormone and prolactin responses to dopaminergic stimulation in Huntington’s chorea. J Clin Endocrinol Metabol 44:870–875
Nagatsu T, Udenfriend S (1972) Photometric assay of dopamine-3hydroxylase activity in human blood. Clin Chem 18:980–983
McNamee B, Kelvin AS, Turnbull MJ (1971) Urinary excretion of some monoamines and metabolites in Huntington’s chorea. Scott Med J 16:247–249
Anton AH, Sayre DF (1962) A study of the factors affecting the aluminum oxide-trihydroxyindole procedure for the analysis of catecholamines. J Pharmacol Exp Ther 138:360–375
Klawans HL (1971) Cerebrospinal fluid homovanillic acid in Huntington’s chorea. J Neurol Sci 13:277–279
Weiner W, Harrison W, Klawans H (1969) l-Dopa and cerebrospinal fluid homovanillic acid in Parkinsonism. Life Sci 8:971–976
Curzon G, Gumpert J, Sharpe D (1972) Amine metabolites in the cerebrospinal fluid in Huntington’s chorea. J Neurol Neurosurg Psychiatry 35:514–519
Curzon G, Godwin-Austen RB, Tomlinson EB, Kantamaneni BD (1970) The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with l-dopa. J Neurol Neurosurg Psychiatry 33:1–6
García Ruiz PJ, Mena MA, Bernardos VS et al (1995) Cerebrospinal fluid homovanillic acid is reduced in untreated Huntingtonʼs disease. Clin Neuropharmacol 18:58–63
Caraceni T, Calderini G, Consolazione A et al (1977) Biochemical aspects of Huntington’s chorea. J Neurol Neurosurg Psychiatry 40:581–587
Korf J, van Praag HM, Sebens JB (1971) Effect of intravenously administered probenecid in humans on the levels of 5-hydroxyindoleacetic acid, homovanillic acid and 3-methoxy-4-hydroxy-phenylglycol in cerebrospinal fluid. Biochem Pharmacol 20:659–668
Markianos M, Panas M, Kalfakis N, Vassilopoulos D (2009) Plasma homovanillic acid and prolactin in Huntington’s disease. Neurochem Res 34:917–922
Williams CM, Maury S, Kibler RF (1961) Normal excretion of homovanillic acid in the urine of patients with Huntington’s chorea. J Neurochem 6:254–256
Pisano JJ, Crout JR, Abraham D (1962) Determination of 3-methoxy-4-hydroxymandelic acid in urine. Clin Chim Acta 7:285–291
Korf J, Valkenburgh-Sikkema T (1969) Fluorimetric determination of 5-hydroxyindoleacetic acid in human urine and cerebrospinal fluid. Clin Chim Acta 26:301–306
Kurlan R, Caine E, Rubin A et al (1988) Cerebrospinal fluid correlates of depression in Huntington’s disease. Arch Neurol 45:881–883
MacFarlane PS, Dalgliesh CE, Dutton RW et al (1956) Endocrine aspects of argentaffinoma, with special reference to the use of urinary 5-hydroxyindoleacetic acid estimations in diagnosis. Scott Med J 1:148–155
Murphy DL, Wright C, Buchsbaum M et al (1976) Platelet and plasma amine oxidase activity in 680 normals: sex and age differences and stability over time. Biochem Med 16:254–265
Varani K, Abbracchio MP, Cannella M et al (2003) Aberrant A2A receptor function in peripheral blood cells in Huntington’s disease. FASEB J 17:2148–2150
Maglione V, Giallonardo P, Cannella M et al (2005) Adenosine A2A receptor dysfunction correlates with age at onset anticipation in blood platelets of subjects with Huntington’s disease. Am J Med Genet B Neuropsychiatr Genet 139b:101–105
Maglione V, Cannella M, Martino T et al (2006) The platelet maximum number of A2A-receptor binding sites (Bmax) linearly correlates with age at onset and CAG repeat expansion in Huntington’s disease patients with predominant chorea. Neurosci Lett 393:27–30
Varani K, Bachoud-Levi AC, Mariotti C et al (2007) Biological abnormalities of peripheral A(2A) receptors in a large representation of polyglutamine disorders and Huntington’s disease stages. Neurobiol Dis 27:36–43
Oates JA, Marsh E, Sjoerdsma A (1962) Studies on histamine in human urine using a fluorometric method of assay. Clin Chim Acta 7:488–497
Beutler BA, Noronha AB, Poon MM, Arnason BG (1981) The absence of unique kainic acid-like molecules in urine, serum, and CSF from Huntington’s disease patients. J Neurol Sci 51:355–360
Reilmann R, Rolf LH, Lange HW (1997) Huntington’s disease: N-methyl-d-aspartate receptor coagonist glycine is increased in platelets. Exp Neurol 144:416–419
Graveland GA, Williams RS, DiFiglia M (1985) Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington’s disease. Science 227:770–773
Manyam NVB, Hare TA, Katz L (1980) Effect of isoniazid on cerebrospinal fluid and plasma GABA levels in Huntington's disease. Life Sci 26:1303–1308
Tell G, Bohlen P, Schechter PJ, Koch-Weser J et al (1981) Treatment of Huntington disease with γ-acetylenic GABA, an irreversible inhibitor of GABA-transaminase: Increased CSF GABA and homocarnosine without clinical amelioration. Neurology 31:207–207
Klawans JHL (1970) A pharmacologic analysis of Huntington’s chorea. Eur Neurol 4:148–163
Borovecki F, Lovrecic L, Zhou J et al (2005) Genome-wide expression profiling of human blood reveals biomarkers for Huntington’s disease. Proc Natl Acad Sci U S A 102:11023–11028
Runne H, Kuhn A, Wild EJ et al (2007) Analysis of potential transcriptomic biomarkers for Huntington’s disease in peripheral blood. Proc Natl Acad Sci U S A 104:14424–14429
Anderson AN, Roncaroli F, Hodges A et al (2008) Chromosomal profiles of gene expression in Huntington’s disease. Brain 131:381–388
Lovrecic L, Kastrin A, Kobal J et al (2009) Gene expression changes in blood as a putative biomarker for Huntington’s disease. Mov Disord 24:2277–2281
Lovrecic L, Slavkov I, Dzeroski S, Peterlin B (2010) ADP-ribosylation factor guanine nucleotide-exchange factor 2 (ARFGEF2): a new potential biomarker in Huntington’s disease. J Int Med Res 38:1653–1662
Hu Y, Chopra V, Chopra R et al (2011) Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse. Proc Natl Acad Sci U S A 108(41):17141–17146
Cesca F, Bregant E, Peterlin B et al (2015) Evaluating the SERCA2 and VEGF mRNAs as potential molecular biomarkers of the onset and progression in Huntington’s disease. PLoS One 10:e0125259
Gaughwin PM, Ciesla M, Lahiri N et al (2011) Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington’s disease. Hum Mol Genet 20:2225–2237
Chen CM, Wu YR, Cheng ML et al (2007) Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington’s disease patients. Biochem Biophys Res Commun 359:335–340
Fang Q, Strand A, Law W, Faca VM et al (2008) Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease. Mol Cell Proteomics 8:451–466
Vinther-Jensen T, Simonsen AH, Budtz-Jørgensen E et al (2015) Ubiquitin: a potential cerebrospinal fluid progression marker in Huntington’s disease. Eur J Neurol 22:1378–1384
Schwarcz R, Tamminga CA, Kurlan R, Shoulson I (1988) Cerebrospinal fluid levels of quinolinic acid in Huntington’s disease and schizophrenia. Ann Neurol 24:580–558
Heyes MP, Swartz KJ, Markey SP, Beal MF (1991) Regional brain and cerebrospinal fluid quinolinic acid concentrations in Huntington’s disease. Neurosci Lett 122:265–269
Heyes MP, Saito K, Crowley JS et al (1992) Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain 115:1249–1273
Heyes MP, Garnett ES, Brown RR (1985) Normal excretion of quinolinic acid in Huntington’s disease. Life Sci 37:1811–1816
Foster AC, Schwarcz R (1985) Characterization of quinolinic acid phosphoribosyltransferase in human blood and observations in Huntington’s disease. J Neurochem 45:199–205
Beal MF, Matson WR, Swartz KJ et al (1990) Kynurenine pathway measurements in Huntington’s disease striatum: evidence for reduced formation of kynurenic acid. J Neurochem 55:1327–1339
Denckla WD, Dewey HK (1967) The determination of tryptophan in plasma, liver, and urine. J Lab Clin Med 69:160–169
Jauch D, Urbanska EM, Guidetti P et al (1995) Dysfunction of brain kynurenic acid metabolism in Huntington’s disease: focus on kynurenine aminotransferases. J Neurol Sci 130:39–47
Reynolds GP, Pearson SJ (1989) Increased brain 3-hydroxykynurenine in Huntington’s disease. Lancet 2:979–980
Pearson SJ, Reynolds GP (1992) Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington’s disease. Neurosci Lett 144:199–201
Guidetti P, Reddy PH, Tagle DA, Schwarcz R (2000) Early kynurenergic impairment in Huntington’s disease and in a transgenic animal model. Neurosci Lett 283:233–235
Fukui S, Schwarcz R, Rapoport SI et al (1991) Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem 56:2007–2017
Jauch DA, Sethy VH, Weick BG et al (1993) Intravenous administration of l-kynurenine to rhesus monkeys: effect on quinolinate and kynurenate levels in serum and cerebrospinal fluid. Neuropharmacology 32:467–472
Vecsei L, Miller J, MacGarvey U, Beal F (1992) Effects of kynurenine and probenecid on plasma and brain tissue concentrations of kynurenic acid. Neurodegeneration 1:17–26
Montine TJ, Markesbery WR, Morrow JD, Roberts LJ (1998) Cerebrospinal fluid F2-isoprostane levels are increased in Alzheimer’s disease. Ann Neurol 44:410–413
Barodia SK, Creed RB, Goldberg MS (2016) Parkin and PINK1 functions in oxidative stress and neurodegeneration. Brain Res Bull 133:51–59
Bozzo F, Mirra A, Carri MT (2017) Oxidative stress and mitochondrial damage in the pathogenesis of ALS: new perspectives. Neurosci Lett 636:3–8
Montine TJ, Beal MF, Robertson D et al (1999) Cerebrospinal fluid F2-isoprostanes are elevated in Huntington’s disease. Neurology 52:1104
Montine TJ, Shinobu L, Montine K et al (2000) No difference in plasma or urinary F2-isoprostanes among patients with Huntington’s disease or Alzheimer’s disease and controls. Ann Neurol 48:950
Hersch SM, Gevorkian S, Marder K et al (2006) Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 66:250–252
Bogdanov M, Brown RH, Matson W et al (2000) Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med 29:652–658
Biglan KM, Dorsey ER, Evans R et al (2012) Plasma 8-hydroxy-2′-deoxyguanosine levels in Huntington disease and healthy controls treated with coenzyme Q10. J Huntingtons Dis 1:65–69
Long JD, Matson WR, Juhl AR et al (2012) 8OHdG as a marker for Huntington disease progression. Neurobiol Dis 46:625–634
Borowsky B, Warner J, Leavitt BR et al (2013) 8OHdG is not a biomarker for Huntington disease state or progression. Neurology 80:1934–1941
Ciancarelli I, De Amicis D, Di Massimo C et al (2014) Peripheral biomarkers of oxidative stress and their limited potential in evaluation of clinical features of Huntington’s patients. Biomarkers 19:452–456
Rosas HD, Doros G, Gevorkian S et al (2014) PRECREST: a phase II prevention and biomarker trial of creatine in at-risk Huntington disease. Neurology 82:850–857
Ciancarelli I, De Amicis D, Di Massimo C et al (2015) Influence of intensive multifunctional neurorehabilitation on neuronal oxidative damage in patients with Huntington’s disease. Funct Neurol 30:47–52
Pena-Sanchez M, Riveron-Forment G, Zaldivar-Vaillant T et al (2015) Association of status redox with demographic, clinical and imaging parameters in patients with Huntington’s disease. Clin Biochem 48:1258–1263
Olsson MG, Davidsson S, Muhammad ZD et al (2012) Increased levels of hemoglobin and alpha1-microglobulin in Huntington’s disease. Front Biosci (Elite Ed) 4:950–957
Witko-Sarsat V, Friedlander M, Nguyen Khoa T et al (1998) Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J Immunol 161:2524–2532
Klepac N, Relja M, Klepac R et al (2007) Oxidative stress parameters in plasma of Huntington’s disease patients, asymptomatic Huntington’s disease gene carriers and healthy subjects: a cross-sectional study. J Neurol 254:1676–1683
Marklund S, Marklund G (1974) Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47:469–474
Aebi H (1984) Catalase in vitro. Methods Enzymol 105:121–126
Paglia DE, Valentine WN (1967) Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 70:158–169
Carlberg I, Mannervik B (1986) Reduction of 2,4,6-trinitrobenzenesulfonate by glutathione reductase and the effect of NADP+ on the electron transfer. J Biol Chem 261:1629–1635
Sedlak J, Lindsay RH (1968) Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman’s reagent. Anal Biochem 25:192–205
Carrizzo A, Di Pardo A, Maglione V et al (2014) Nitric oxide dysregulation in platelets from patients with advanced Huntington disease. PLoS One 9:e89745
Radomski M, Moncada S (1983) An improved method for washing of human platelets with prostacyclin. Thromb Res 30:383–389
Banegas I, Prieto I, Vives F et al (2004) Plasma aminopeptidase activities in rats after left and right intrastriatal administration of 6-hydroxydopamine. Neuroendocrinology 80:219–224
Reilmann R, Rolf LH, Lange HW (1994) Huntington’s disease: the neuroexcitotoxin aspartate is increased in platelets and decreased in plasma. J Neurol Sci 127:48–53
Kim JS, Kornhuber HH, Holzmuller B et al (1980) Reduction of cerebrospinal fluid glutamic acid in Huntington’s chorea and in schizophrenic patients. Arch Psychiatr Nervenkr 228:7–10
Graham LT Jr, Aprison MH (1966) Fluorometric determination of aspartate, glutamate, and gamma-aminobutyrate in nerve tissue using enzymic methods. Anal Biochem 15:487–497
Uhlhaas S, Lange H (1988) Striatal deficiency of l-pyroglutamic acid in Huntington’s disease is accompanied by increased plasma levels. Brain Res 457:196–199
Huntington Study Group T-HDI (2008) Randomized controlled trial of ethyl-eicosapentaenoic acid in Huntington disease: the TREND-HD study. Arch Neurol 65:1582–1589
Puri BK, Leavitt BR, Hayden MR et al (2005) Ethyl-EPA in Huntington disease: a double-blind, randomized, placebo-controlled trial. Neurology 65:286–292
Ferreira JJ, Rosser A, Craufurd D et al (2015) Ethyl-eicosapentaenoic acid treatment in Huntington’s disease: a placebo-controlled clinical trial. Mov Disord 30:1426–1429
Hyson HC, Kieburtz K, Shoulson I et al (2010) Safety and tolerability of high-dosage coenzyme Q10 in Huntington’s disease and healthy subjects. Mov Disord 25:1924–1928
McGarry A, McDermott M, Kieburtz K et al (2017) A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology 88:152–159
Huntington Study Group (2001) A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington’s disease. Neurology 57:397–404
Li SH, Schilling G, Young WS et al (1993) Huntington’s disease gene (IT15) is widely expressed in human and rat tissues. Neuron 11:985–993
van der Burg JM, Bjorkqvist M, Brundin P (2009) Beyond the brain: widespread pathology in Huntington’s disease. Lancet Neurol 8:765–774
Sathasivam K, Hobbs C, Turmaine M et al (1999) Formation of polyglutamine inclusions in non-CNS tissue. Hum Mol Genet 8:813–822
Keogh HJ, Johnson RH, Nanda RN, Sulaiman WR (1976) Altered growth hormone release in Huntington’s chorea. J Neurol Neurosurg Psychiatry 39:244–248
Phillipson OT, Bird ED (1976) Plasma growth hormone concentrations in Huntington’s chorea. Clin Sci Mol Med 50:551–554
Hartog M, Gaafar MA, Meisser B, Fraser R (1964) Immunoassay of serum growth hormone in acromegalic patients. Br Med J 2:1229–1232
Chalmers RJ, Johnson RH, Keogh HJ, Nanda RN (1978) Growth hormone and prolactin response to bromocriptine in patients with Huntington’s chorea. J Neurol Neurosurg Psychiatry 41:135–139
Muller EE, Parati EA, Panerai AE et al (1979) Growth hormone hyperresponsiveness to dopaminergic stimulation in Huntington’s chorea. Neuroendocrinology 28:313–319
Murri L, Iudice A, Muratorio A et al (1980) Spontaneous nocturnal plasma prolactin and growth hormone secretion in patients with Parkinson’s disease and Huntington’s chorea. Eur Neurol 19:198–206
Lavin PJ, Bone I, Sheridan P (1981) Studies of hypothalamic function in Huntington’s chorea. J Neurol Neurosurg Psychiatry 44:414–418
Durso R, Tamminga CA, Ruggeri S et al (1983) Twenty-four hour plasma levels of growth hormone and prolactin in Huntington’s disease. J Neurol Neurosurg Psychiatry 46:1134–1137
Durso R, Tamminga CA, Denaro A et al (1983) Plasma growth hormone and prolactin response to dopaminergic GABAmimetic and cholinergic stimulation in Huntington’s disease. Neurology 33:1229–1232
Popovic V, Svetel M, Djurovic M et al (2004) Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington’s disease. Eur J Endocrinol 151:451–455
Saleh N, Moutereau S, Durr A et al (2009) Neuroendocrine disturbances in Huntington’s disease. PLoS One 4:e4962
Aziz NA, Pijl H, Frolich M et al (2010) Growth hormone and ghrelin secretion are associated with clinical severity in Huntington’s disease. Eur J Neurol 17:280–288
Saleh N, Moutereau S, Azulay JP et al (2010) High insulinlike growth factor I is associated with cognitive decline in Huntington disease. Neurology 75:57–63
Salvatore E, Rinaldi C, Tucci T et al (2011) Growth hormone response to arginine test differentiates between two subgroups of Huntington’s disease patients. J Neurol Neurosurg Psychiatry 82:543–547
Russo CV, Salvatore E, Sacca F et al (2013) Insulin sensitivity and early-phase insulin secretion in normoglycemic Huntington’s disease patients. J Huntingtons Dis 2:501–507
Hayden MR, Vinik AI, Paul M, Beighton P (1977) Impaired prolactin release in Huntington’s chorea. Evidence for dopaminergic excess. Lancet 2:423–426
Caine E, Kartzinel R, Ebert M, Carter AC (1978) Neuroendocrine function in Huntington’s disease: dopaminergic regulation of prolactin release. Life Sci 22:911–918
Kremer HP, Roos RA, Frolich M et al (1989) Endocrine functions in Huntington’s disease. A two-and-a-half years follow-up study. J Neurol Sci 90:335–344
Aziz NA, Pijl H, Frolich M, Roelfsema F, Roos RA (2010) Altered thyrotropic and lactotropic axes regulation in Huntington’s disease. Clin Endocrinol 73:540–545
Heuser IJ, Chase TN, Mouradian MM (1991) The limbic-hypothalamic-pituitary-adrenal axis in Huntington’s disease. Biol Psychiatry 30:943–952
Gold PW, Calabrese JR, Kling MA et al (1986) Abnormal ACTH and cortisol responses to ovine corticotropin releasing factor in patients with primary affective disorder. Prog Neuro-Psychopharmacol Biol Psychiatry 10:57–65
Bruyn GW, de Yong FH, van der Molen JH (1972) Huntington’s chorea and the adrenal. Br Med J 1:506
Leblhuber F, Peichl M, Neubauer C et al (1995) Serum dehydroepiandrosterone and cortisol measurements in Huntington’s chorea. J Neurol Sci 132:76–79
Markianos M, Panas M, Kalfakis N, Vassilopoulos D (2007) Plasma testosterone, dehydroepiandrosterone sulfate, and cortisol in female patients with Huntington’s disease. Neuro Endocrinol Lett 28:199–203
Aziz NA, Pijl H, Frolich M et al (2009) Increased hypothalamic-pituitary-adrenal axis activity in Huntington’s disease. J Clin Endocrinol Metabol 94:1223–1228
Markianos M, Panas M, Kalfakis N, Vassilopoulos D (2005) Plasma testosterone in male patients with Huntington’s disease: relations to severity of illness and dementia. Ann Neurol 57:520–525
Aziz NA, Pijl H, Frolich M et al (2010) Leptin secretion rate increases with higher CAG repeat number in Huntington’s disease patients. Clin Endocrinol 73:206–211
Gaus SE, Lin L, Mignot E (2005) CSF hypocretin levels are normal in Huntington’s disease patients. Sleep 28:1607–1608
Björkqvist M, Petersén Å, Nielsen J et al (2006) Cerebrospinal fluid levels of orexin-A are not a clinically useful biomarker for Huntington disease. Clin Genet 70:78–79
Björkqvist M, Leavitt BR, Nielsen JE et al (2007) Cocaine- and amphetamine-regulated transcript is increased in Huntington disease. Mov Disord 22:1952–1954
Ciammola A, Sassone J, Cannella M et al (2007) Low brain-derived neurotrophic factor (BDNF) levels in serum of Huntington’s disease patients. Am J Med Genet 144B:574–577
Squitieri F, Cannella M, Simonelli M et al (2009) Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington’s disease. CNS Neurosci Ther 15:1–11
Zuccato C, Marullo M, Vitali B et al (2011) Brain-derived neurotrophic factor in patients with Huntington’s disease. PLoS One 6:e22966
Lorigados L, Soderstrom S, Ebendal T (1992) Two-site enzyme immunoassay for beta NGF applied to human patient sera. J Neurosci Res 32:329–339
Battista N, Bari M, Tarditi A et al (2007) Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes. Neurobiol Dis 27:108–116
Wood NI, Goodman AO, van der Burg JM et al (2008) Increased thirst and drinking in Huntington’s disease and the R6/2 mouse. Brain Res Bull 76:70–79
Lalic NM, Maric J, Svetel M et al (2008) Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion. Arch Neurol 65:476–480
Podolsky S, Leopold NA (1977) Abnormal glucose tolerance and arginine tolerance tests in Huntington’s disease. Gerontology 23:55–63
Kunst A, Draeger B, Ziegenhorn J (1974) In: Bergmayer HU, Bergmayer J, Grassl M (eds) Methods of enzymatic analysis, vol 6. Verlag Chemie, Weinheim, pp 163–172
Fraser S, Cowen P, Franklin M et al (1983) Direct radioimmunoassay for melatonin in plasma. Clin Chem 29:396–397
Aziz NA, Pijl H, Frolich M et al (2009) Delayed onset of the diurnal melatonin rise in patients with Huntington’s disease. J Neurol 256:1961–1965
Kalliolia E, Silajdzic E, Nambron R et al (2014) Plasma melatonin is reduced in Huntington’s disease. Mov Disord 29:1511–1515
Aziz NA, Onkenhout W, Kerstens HJ, Roos RA (2015) Cystathionine levels in patients with Huntington disease. PLoS Curr 7. https://doi.org/10.1371/currents.hd.c63b441d04bb6738c0234f91c2b3e312
Merens W, Booij L, Markus R et al (2005) The effects of a diet enriched with alpha-lactalbumin on mood and cortisol response in unmedicated recovered depressed subjects and controls. Br J Nutr 94:415–422
Forrest AD (1957) Some observations on Huntington’s chorea. J Ment Sci 103:507–513
Bruyn GW, Mink CJ, Calje JF (1965) Biochemical studies in Huntington’s chorea: erythrocyte magnesium. Neurology 15:455–461
Bonilla E, Estevez J, Suarez H et al (1991) Serum ferritin deficiency in Huntington’s disease patients. Neurosci Lett 129:22–24
Morrison PJ, Nevin NC (1994) Serum iron, total iron binding capacity and ferritin in early Huntington disease patients. Ir J Med Sci 163:236–237
Leoni V, Mariotti C, Tabrizi SJ et al (2008) Plasma 24S-hydroxycholesterol and caudate MRI in pre-manifest and early Huntington’s disease. Brain 131:2851–2859
Markianos M, Panas M, Kalfakis N, Vassilopoulos D (2008) Low plasma total cholesterol in patients with Huntington’s disease and first-degree relatives. Mol Genet Metab 93:341–346
Leoni V, Mariotti C, Nanetti L et al (2011) Whole body cholesterol metabolism is impaired in Huntington’s disease. Neurosci Lett 494:245–249
Laurell S, Tibbling G (1967) Colorimetric micro-determination of free fatty acids in plasma. Clin Chim Acta 16:57–62
Kim J, Amante DJ, Moody JP et al (2010) Reduced creatine kinase as a central and peripheral biomarker in Huntington’s disease. Biochim Biophys Acta 1802:673–681
Petersen A, Bjorkqvist M (2006) Hypothalamic-endocrine aspects in Huntington’s disease. Eur J Neurosci 24:961–967
Karege F, Schwald M, Cisse M (2002) Postnatal developmental profile of brain-derived neurotrophic factor in rat brain and platelets. Neurosci Lett 328:261–264
Lazar AS, Panin F, Goodman AO et al (2015) Sleep deficits but no metabolic deficits in premanifest Huntington’s disease. Ann Neurol 78:630–648
US FDA (2001) Guidance for industry: bioanalytical method validation. Rockville, MD, USA
European Medicines Agency (2011) Guideline on bioanalytical method validation. London, UK
University College L (2017) HDClarity: a multi-site cerebrospinal fluid collection initiative to facilitate therapeutic development for Huntington’s disease. https://ClinicalTrials.gov/show/NCT02855476
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC, part of Springer Nature
About this protocol
Cite this protocol
Rodrigues, F.B., Byrne, L.M., Wild, E.J. (2018). Biofluid Biomarkers in Huntington’s Disease. In: Precious, S., Rosser, A., Dunnett, S. (eds) Huntington’s Disease. Methods in Molecular Biology, vol 1780. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7825-0_17
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7825-0_17
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7824-3
Online ISBN: 978-1-4939-7825-0
eBook Packages: Springer Protocols